Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole blood transfusion Clear all
Terminated Phase 2 Interventional Results available

Control of Major Bleeding After Trauma Study

NCT01838863
View directory record Official record
Conditions
Trauma, Hemorrhagic Shock
Interventions
Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
Biological · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

NCT02889133
View directory record Official record
Conditions
Iron Deficiency
Interventions
Iron-dextran, Saline, Blood Donation, 24-hour PTR
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)

NCT02280655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?

NCT02918851
View directory record Official record
Conditions
Healthy
Interventions
Transfusion of 7-day stored red blood cells, Transfusion of 28-day stored red blood cells, Transfusion of 42-day stored red blood cells
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

ECMO Hemostatic Transfusions in Children

NCT05796557
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Thromboembolism, Transfusion Adverse Reaction
Interventions
Platelet Transfusion
Biological
Lead sponsor
Yale University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 14, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Stroke With Transfusions Changing to Hydroxyurea

NCT00122980
View directory record Official record
Conditions
Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions
Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

NCT00133367
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia
Interventions
Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 14, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

NCT02074436
View directory record Official record
Conditions
Hematological Malignancies, Thrombocytopenia
Interventions
EACA, Platelet transfusion
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 14, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

NCT00953771
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Danazol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 14, 2026, 3:32 PM EDT
Recruiting No phase listed Observational

Antibiotic Concentrations After MassivE Transfusion Study

NCT06699901
View directory record Official record
Conditions
Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents
Interventions
Massive Transfusion Group, Control Group
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for the Treatment of Bleeding in HHT

NCT03910244
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pomalidomide Oral Product, Placebo oral capsule
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 14, 2026, 3:32 PM EDT
Not listed Not applicable Interventional

Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions

NCT01453309
View directory record Official record
Conditions
Low Back Pain Unresponsive to Non-surgical Care
Interventions
Cell Saver, No Cell Saver
Procedure
Lead sponsor
Norton Leatherman Spine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion Pilot

NCT01167582
View directory record Official record
Conditions
Myocardial Infarction, Unstable Angina, Coronary Artery Disease
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 14, 2026, 3:32 PM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 3:32 PM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT02887820
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Red Blood Cell (RBC) Survival Following Transfusion in Infants

NCT00731588
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
Biological
Lead sponsor
John A Widness
Other
Eligibility
1 Hour to 6 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Transfusion of Prematures Trial

NCT01702805
View directory record Official record
Conditions
Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia
Interventions
Liberal Cell Transfusion, Restricted red cell transfusion
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
1,824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

NCT03897205
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 14, 2026, 3:32 PM EDT
Not listed Not applicable Interventional

Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management

NCT01686659
View directory record Official record
Conditions
Surgery
Interventions
Continuous Noninvasive Hemoglobin Monitoring
Device
Lead sponsor
Society for the Advancement of Blood Management, Inc
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Stanford, California • The Bronx, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

NCT01714336
View directory record Official record
Conditions
Hip Fracture
Interventions
tranexamic acid, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions

NCT01211366
View directory record Official record
Conditions
Transfusion
Interventions
Cell Saver RBCs, Conventional volume infusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 14, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

NCT03923959
View directory record Official record
Conditions
Hip Fractures
Interventions
Tranexamic Acid Injectable Solution, Placebo
Drug · Other
Lead sponsor
Lancaster General Hospital
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 14, 2026, 3:32 PM EDT
Withdrawn Early Phase 1 Interventional

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

NCT04383756
View directory record Official record
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 14, 2026, 3:32 PM EDT